Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EPRX |
---|---|---|
10:46 ET | 1000 | 4.14 |
11:04 ET | 200 | 4.15 |
11:15 ET | 3200 | 4.15 |
11:20 ET | 900 | 4.15 |
11:31 ET | 3000 | 4.14 |
12:23 ET | 5000 | 4.15 |
12:43 ET | 3100 | 4.15 |
12:56 ET | 200 | 4.15 |
01:10 ET | 600 | 4.13 |
01:12 ET | 100 | 4.18 |
01:14 ET | 700 | 4.21 |
01:39 ET | 9900 | 4.29 |
01:42 ET | 2000 | 4.3 |
02:00 ET | 15000 | 4.3 |
03:20 ET | 4200 | 4.35 |
03:21 ET | 19600 | 4.22 |
03:57 ET | 1400 | 4.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Eupraxia Pharmaceuticals Inc | 148.9M | -3.1x | --- |
Alpha Cognition Inc | 116.8M | -4.0x | --- |
Zentek Ltd | 161.3M | -13.5x | --- |
NervGen Pharma Corp | 130.9M | -6.6x | --- |
Arch Biopartners Inc | 138.1M | -71.8x | --- |
Cardiol Therapeutics Inc | 170.4M | -5.6x | --- |
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Company’s principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $151.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.5M |
Eupraxia Pharmaceuticals Inc does not pay a dividend. | |
Beta | --- |
EPS | $-1.39 |
Book Value | $0.60 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.